Brief: EMA's CHMP Recommends Extension Of Therapeutic Indication For Pfizer's Hympavzi

Amgen

27/03/2026 11:56

March 27 (Reuters) - EMA's CHMP:

EMA'S CHMP: RECOMMENDED GRANTING MARKETING AUTHORISATION FOR IMDYLLTRA (TARLATAMAB) FOR TREATMENT OF RELAPSED EXTENSIVE-STAGE SMALL CELL LUNG CANCER

EMA'S CHMP: CONFIRMED RECOMMENDATION TO REFUSE A CHANGE TO MARKETING AUTHORISATION FOR HETLIOZ (TASIMELTEON)

EMA'S CHMP: CONFIRMED ITS RECOMMENDATION TO REFUSE A CHANGE TO THE MARKETING AUTHORISATION FOR HETLIOZ (TASIMELTEON)

EMA'S CHMP: JOENJA (LENIOLISIB) RECEIVED POSITIVE OPINION FOR MARKETING AUTHORISATION UNDER EXCEPTIONAL CIRCUMSTANCES

EMA'S CHMP: APPLICATION FOR INITIAL MARKETING AUTHORISATION OF BLARCAMESINE ANAVEX WAS WITHDRAWN.

EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR HYMPAVZI

Further company coverage: AMGN.O

 ((Reuters.Briefs@thomsonreuters.com;))